Publication number: 20260294922
Abstract: The present disclosure relates, in part, to compounds of Formula (I) and (II), which selectively inhibit JUN N-Terminal Kinases (JNK1, JNK2, and/or JNK3; also known as MAPK8, MAPK9, and/or MAPK10), pharmaceutical compositions thereof, and methods of using the same for the treatment, prevention, and/or amelioration of one or more diseases and/or disorders in a subject. In certain embodiments, the inflammatory disease or disorder is endometriosis, arthritis, pulmonary fibrosis, cancer, type 1 and/or 2 diabetes, Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis. In certain embodiments, the methods described herein further comprise detecting the disease and/or disorder in the subject with a suitable diagnostic method.
Type:
Application
Filed:
April 24, 2024
Publication date:
October 1, 2026
Inventors:
Chandra Madasu, Stephen Palmer, Martin Matzuk, Diana Monsivais, Kurt Bohren, Zhi Tan, Jian-Yuan Li, Feng Li, Damian Young, Kiran Sharma, Murugesan Palaniappan, Srinivas Chamakuri, Ramakrishna Kommagani